Lexeo Therapeutics, Inc. Income Statement

Income Statement Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 0.65M-0.20M-0.14M
Gross Profit 0.65M-0.20M-0.14M
Operating items
Research & Development 49.16M53.13M74.09M
Selling, General & Administrative 12.00M15.38M31.68M
Restructuring Costs 9.51M18.52M
Other Operating Expenses -9.51M-18.52M
Operating Expenses 61.16M68.51M105.77M
Operating Income -60.51M-68.51M-105.77M
EBIT -60.51M-68.51M-105.77M
Non-operating items
Non Operating Investment Income -0.10M
Interest & Investment Income 1.32M2.87M7.56M
Other Non Operating Income -0.00M-0.01M-0.01M
Non Operating Income 1.23M2.12M7.43M
Net income details
EBT -59.28M-66.39M-98.33M
Profit After Tax -59.30M-66.40M-98.33M
Income from Continuing Operations -59.28M-66.39M-98.33M
Consolidated Net Income -59.28M-66.39M-98.33M
Income towards Parent Company -59.28M-66.39M-98.33M
Net Income towards Common Stockholders -59.28M-66.39M-98.33M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 15.67M26.65M33.07M
Shares Outstanding (Diluted Average) 1.63M
EBITDA -60.51M-66.39M-98.44M